<DOC>
	<DOC>NCT02231671</DOC>
	<brief_summary>The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.</brief_summary>
	<brief_title>A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Body mass index 18.0 to 32.0 kg/m2 (inclusive) and a total body weight &gt;50 kg Creatinine clearance as calculated by the Cockroft‚ÄêGault formula of less than 60 mL/min Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator or the sponsor medical monitor. Reticulocyte count, haemoglobin and platelet counts must not be less than the lower limit of normal for the subject. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory, GI, haematological, neurological, endocrinological, immunological, musculoskeletal disease or any uncontrolled medical illness (eg active infection) or psychiatric disorder, as judged by the investigator or medical monitor. Clinically significant abnormal electrocardiogram (ECG) findings</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>